A patent attorney and business entrepreneur, James Cullem has recently expanded his reach with the creation and development of Sierra Glycomics. Sierra Glycomics is an analytic services firm that supports the drug development and biofuels industries. James Cullem earlier was the co-founder and chief executive office of two biotech start-ups, Halcyon Diagnostics and Paradigm Oncology. James Cullem formerly held the position of Chief Corporate Counsel in two companies focused on life sciences. He is a Juris Doctorate recipient and proud graduate of the top patent program at Franklin Pierce Law Center, which has since been folded into the University of New Hampshire law school.<br /> <br />For twenty-plus years, James Cullem amassed an impressive list of achievements within the biotechnology arena as a Founder & Managing Principal for Aurora Nova, LLC, Director of Licensing & Intellectual Property (I.P.) and Chief Counsel for Cell Signaling Technology, Inc. and Director of Corporate Development and General Counsel for Enzymatics, Inc. James Cullem is uniquely adept at managing projects related to patents, trademarks, licensing and commercialization for technology purposes. His accomplishments include securing seven-figure partnerships with a host of Fortune 500 businesses. Given his wide-ranging background and business relationships, James Cullem is recognized for his ability to solve business and I.P. asset challenges facing many of today’s early-to-mid-stage biotechnology firms.